Results 91 to 100 of about 33,329 (197)
BMC Cancer, 2019 Background The CD133 transmembrane protein is a well-recognized stem cell marker that has been used to isolate putative cancer stem cell populations from gastric cancers (GCs).
Tae-Min Kim +3 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang +10 more
wiley +1 more source
CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma
CellsCD133, a cancer stem cell (CSC) marker in tumors, including melanoma, is associated with tumor recurrence, chemoresistance, and metastasis. Patient-derived melanoma cell lines were transduced with a Tet-on vector expressing CD133, generating doxycycline (
Cynthia M Simbulan-Rosenthal +8 more
doaj +1 more source
Journal of International Medical Research, 2018 Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong +3 more
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.An improved and simplified method enables the generation of primary tumor cells and tumoroids from the same tissue sample with minimal input, applicable universally to both intracranial and spinal tumors. Comparative analysis of drug screening results with patient follow‐up data allows for the assessment of individual drug sensitivity.
Siyuan Wang +9 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may enhance selective targeting of ...
Subham Sarkar +5 more
wiley +1 more source
Mechanism of ORC1 Regulating Cancer Stemness and Cisplatin Resistance in Non‐Small Cell Lung Cancer
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 10, October 2026.Elevated ORC1 expression in non‐small cell lung cancer (NSCLC) simultaneously activates cancer stemness and epithelial‐mesenchymal transition (EMT). Upregulation of stemness‐associated factors (NANOG, LGR5, CD133+CD44+ CSCs) and EMT transcription factors (SNAI1, SNAI2, TWIST1) synergistically induce MDR1 overexpression. Increased MDR1 ultimately drives
Jianhui Sheng, Yingjian Song
wiley +1 more source
Journal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.First‐trimester trophoblast EVs are enriched in anti‐inflammatory proteins, lipids, and immunoregulatory miRNAs. EVT‐EVs reprogram monocytes toward a pro‐resolving phenotype and restore immune homeostasis in RDEB, supporting their potential as offering a scalable off‐the‐shelf therapy for chronic inflammatory diseases.
Nell Hirt +8 more
wiley +1 more source
Only anti-CD133 antibodies recognizing the CD133/1 or the CD133/2 epitopes can identify human renal progenitors [PDF]
Kidney International, 2010 ANGELOTTI, MARIA LUCIA +3 more
openaire +5 more sources
eJHaem, Volume 7, Issue 5, October 2026.ABSTRACT Umbilical cord blood transplantation is a viable source of stem cells due to accessibility and low incidence of chronic graft‐versus‐host disease despite human‐leukocyte‐antigen mismatching. Disadvantages of low stem cell dose in larger recipients include delayed immune reconstitution, graft rejection, and mortality.
Rachel E. Granberg +4 more
wiley +1 more source